微芯生物(688321.SH):CS12192臨牀試驗申請獲得受理
格隆匯3月24日丨微芯生物(688321.SH)公佈,公司及全資子公司成都微芯藥業有限公司今日收到國家藥品監督管理局(“國家藥監局”)簽發的《受理通知書》,產品名稱為CS12192膠囊。
CS12192是微芯生物自主研發的已獲全球化合物發明專利授權的高選擇性JAK3激酶抑制劑,同時部分抑制JAK1和TBK1激酶,目前尚沒有此類抑制劑藥物上市。
已完成的臨牀前研究表明,CS12192在類風濕性關節炎、多發性硬化病、系統性紅斑狼瘡、銀屑病等自身免疫性疾病模型及移植物抗宿主疾病(GVHD)模型上均具有明顯的藥效活性,在部分疾病模型上顯示出有別於其他JAK激酶抑制劑的差異化藥效特徵。CS12192不但能有效抑制免疫細胞過度活化介導的炎症,同時通過抑制TBK1減輕免疫細胞的組織侵襲,有望為自身免疫相關性疾病臨牀治療提供一種新的差異化治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.